$DARE News

Last published 1d ago

1d agoDAREDaré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026GlobeNewswireSAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the...
2d agoDAREDaré Bioscience Releases Next Episode in “CEO Corner” Video SeriesGlobeNewswireSabrina Martucci Johnson, Founder, President and CEO, discusses numerous potential value drivers expected to power the Company’s next phase of growth and commercial success Access the CEO Corner here SAN DIEGO, Nov.
2d agoDAREDaré Bioscience Releases Next Episode in “CEO Corner” Video SeriesGlobeNewswireSabrina Martucci Johnson, Founder, President and CEO, discusses numerous potential value drivers expected to power the Company’s next phase of growth and commercial success
1w agoDAREDaré Bioscience to Present at Stifel’s 2026 Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and
1w agoDAREDaré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains MomentumGlobeNewswireLatest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development Company Exploring Potential Strategic Collaborations for DARE-IDDS Platform in Obesity, Diabetes
2w agoDAREDaré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” DiscussionGlobeNewswireSabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience’s growing commercial portfolio and clinical pipeline position the Company to address
2w agoDAREDaré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled WirelesslyGlobeNewswireA single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program VP of Product Development Liz Proos presents Friday, October 30, at 2:30
3w agoDAREDaré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast CancerGlobeNewswirePremier sponsorship of the HERmedicine and OncoMenopause Consortium® program underscores Daré Bioscience's commitment to addressing unmet women’s health needs, including for women affected by breast cancer The
4w agoDAREDaré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and OpportunitiesGlobeNewswireNew video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience’s growing commercial portfolio, clinical pipeline and strategic priorities Access
1mo agoDAREDaré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific MeetingGlobeNewswireSAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and
1mo agoDAREDaré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral SildenafilGlobeNewswirePublished Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6% At the 71 mg topical dose, mean maximum plasma concentration of sildenafil
2mo agoDAREDaré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm BirthGlobeNewswireNew NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million DARE-PTB2 is an early-stage,
2mo agoDAREDaré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand SeriesGlobeNewswireVideo webcast now available here SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health
2mo agoAIM AKTX CNSP DARE+5JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsACCESS NewswireNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming
2mo agoDAREDaré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause SocietyGlobeNewswireDaré’s proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposureCompany continues activities necessary to advance its
2mo agoDAREDaré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect SegmentGlobeNewswirePresident & CEO, Sabrina Martucci Johnson, discusses the Company’s shift to commercial stage, upcoming revenue opportunities, Ovaprene’s positive interim Phase 3 results and what could drive value over the next
2mo agoDAREDARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” ListGlobeNewswireSAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and
2mo agoDAREDaré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireSAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world
3mo agoDAREDARÉ BIOSCIENCE, INC. Q2 2026 CONFERENCE CALL - DARE BIOSCIENCE INCEarnings Call TranscriptsHello and welcome to the Data Bioscience second quarter 2026 corporate update conference call and webcast. As a brief reminder, all participants are in a listen-only mode. Following the presentation, there will be a ques
3mo agoDAREDaré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy AdvancesGlobeNewswireCompany launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July DARE to PLAY™ Sildenafil Cream progressing toward national dispensing and initial revenue in
3mo agoDAREDaré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026GlobeNewswireSAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and
3mo agoDAREDaré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRxGlobeNewswireA featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing Daré’s strategy to build a trusted women’s health ecosystem spanning products, education and access to care
3mo agoDAREDaré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth OpportunitiesGlobeNewswireSAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and
4mo agoDAREDaré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell EventGlobeNewswireLive video webcast on Tuesday, July 14th, at 4:00 PM ETRegister here SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on
4mo agoDAREDaré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer PlatformGlobeNewswireSAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world
4mo agoDAREDaré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” SegmentGlobeNewswireFirst consumer health product positions Daré for revenue generation while expanding its women's health leadership platform Access the segment here SAN DIEGO, June 25, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience,
4mo agoDAREDaré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026GlobeNewswireSAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world
5mo agoDAREDaré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic CapsulesGlobeNewswireFirst Product Revenue Expected This Month, Opening New Commercial Chapter for Women's Health Innovator Limited-Time Launch Offer: 30% Off + Free Shipping SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Daré
5mo agoDAREDaré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical CancerGlobeNewswireReceipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of the initiation of
5mo agoDAREDaré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved TherapiesGlobeNewswireEach year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. government (ARPA-H)-funded
6mo agoDAREDaré Bioscience Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireCompany Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer
6mo agoDAREPositive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free ContraceptiveGlobeNewswireSecond Positive DSMB Review Supports Continued Study Progress Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive SAN DIEGO, May 12, 2026
6mo agoDAREDaré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026GlobeNewswireSAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world
7mo agoDAREDaré Bioscience Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireCompany Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET
7mo agoDAREOn National Viagra Day, Women Finally Claim Their Turn:GlobeNewswireSAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Every year on March 27th, National Viagra Day celebrates a drug that transformed sexual health for millions of men. Today, Daré Bioscience, Inc. (NASDAQ:DARE), a
8mo agoDAREDaré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm BirthGlobeNewswire• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026• DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options• Award reflects
8mo agoDAREDaré Bioscience Participates in Virtual Investor "What This Means" SegmentGlobeNewswireSabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women's healthAccess the segment
8mo agoDAREDaré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical CancerGlobeNewswireSAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world
9mo agoDARETelehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for WomenGlobeNewswireDeveloped and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in
11mo agoDAREDARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing FacilityGlobeNewswireDeveloped and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in
11mo agoDAREDaré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-MaximizationGlobeNewswireSAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world
11mo agoDAREDaré Bioscience Receives $3.6 Million in Additional Grant FundingGlobeNewswireSAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world
12mo agoDAREDaré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireDARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued
1y agoDAREDaré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025GlobeNewswireSAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real
1y agoDAREDaré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape AssessmentGlobeNewswireSAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world
1y agoDAREDaré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic DisordersGlobeNewswireSAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions,
1y agoDAREDaré Bioscience to Receive up to $499,000 to Support Preeclampsia ResearchGlobeNewswireSAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions,
1y agoDAREDaré Bioscience, Inc. (DARE) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoDAREDaré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireDARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports
1y agoDAREDaré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025GlobeNewswireSAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will